

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average burden nours per response 0.5					
nours per response					

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respor	ises)											
Name and Address of Reporting Person *  Ward Keith Wayne			2. Date of Event Requiring Statement (Month/Day/Year) 12/14/2021		3. Issuer Name and Ticker or Trading Symbol Skye Bioscience, Inc. [SKYE]							
11250 EL CAMI	(First) NO REAL,	(Middle) , SUITE 100	4. Relation Issuer			Issuer	ssuer			5. If Amendment, Date Original Filed(Month/Day/Year)		
SAN DIEGO, CA	(Street)						(Check _X_ Director Officer (give tit below)	eck all applicable) e titleOther (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
(City)	(State)	(Zip)	Table I			able I	I - Non-Derivative Securities Beneficially Owned				, ,	
1.Title of Security (Instr. 4)				ally Ow	ned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature (Instr. 5)	. Nature of Indirect Beneficial Ownership Instr. 5)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  SEC 1473 (7-02)  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative (Instr. 4)	3		nd Expirati			Amount of iderlying Derivativ	4. Conversion or Exercise Price of Derivative	Form of Deriva	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
				Expiration Date	Title	Amour	nt or Number of	Security	(D) or (I) (Instr.	Indirect 5)		

## **Reporting Owners**

Panarting Owner Name /	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Ward Keith Wayne 11250 EL CAMINO REAL SUITE 100 SAN DIEGO, CA 92130	X					

## **Signatures**

/s/ Kaitlyn Arsenault, as Attorney-in-Fact	12/16/2021
**Signature of Reporting Person	Date

# **Explanation of Responses:**

### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

### Remarks:

No securities are beneficially owned. Exhibit 24 - Power of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

### **POWER OF ATTORNEY**

Know all by these present, that the undersigned hereby constitutes and appoints each of Kaitlyn Arsenault and Punit Dhillon, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Skye Bioscience, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of December, 2021.

DocuSigned by:	
Keith Ward	
746983C49557474 Signature	
Keith Ward	
Name	